Table 2.
Number of Doses Administered and Neurological Response After 8 Weeks of IT Trastuzumab
| Pt. no. | No. of doses administered | Clinical neurological response | Radiological neurological response | Early termination reason |
|---|---|---|---|---|
| 1 | 17 | RD | SD | |
| 2 | 1 | PD | n/a | Death |
| 3 | 7 | SD | n/a | 8th administration omitted |
| 4 | 25 | SD | SD | |
| 5 | 32 | SD | SD | |
| 6 | 8 | PD | SD | |
| 7 | 8 | SD | RDa | |
| 8 | 6 | RD | n/a | Meningeal progressionb |
| 9 | 8 | SD | PD | |
| 10 | 8 | PD | RDa | |
| 11 | 8 | RD | SD | |
| 12 | 6 | SD | PD | Meningeal progressionb |
| 13 | 4 | SD | n/a | Cerebral progression |
| 14 | 23 | SD | SD | |
| 15 | 8 | SD | SD | |
| 16 | 8 | SD | SD | |
| 17 | 8 | RD | SD | |
| 18 | 8 | PD | SD | |
| 19 | 1 | PD | n/a | Death |
Abbreviations: n/a, not applicable; PD, progressive disease; RD, responsive disease; SD, stable disease. In light gray, patients without clinical neurological progression after 8 weeks of treatment.
aResponsive disease during the radiological assessment corresponded to partial response, according to the RECIST criteria for these 2 patients.
bBiological and/or radiological meningeal progression without clinical progression.